Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 BioMarin Completes Acquisition of Inozyme Pharma for $270M | Contract Pharma

What are you searching for?

Sign in
Breaking News

BioMarin Completes Acquisition of Inozyme Pharma for $270M

Strengthens BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

BioMarin Pharmaceutical Inc. has completed the previously announced agreement to acquire Inozyme Pharma Inc. for $4.00 per share in an all-cash transaction worth approximately $270 million.

The acquisition will strengthen BioMarin’s enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701, which is currently being developed for the treatment of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) Deficiency, a rare, serious, and progressive genetic condition that affects blood vessels, soft tissues, and bones.

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics